Tag: CAR-T
Miltenyi Biotec India and BIRAC sign LoI to advance India’s cell...
The partnership will focus on building local scientific capabilities, CAR-T clinical trials, addressing unmet medical needs and enhancing access through PoC manufacturing centers to strengthen India’s CGT capabilities
Immuneel Therapeutics launches Qartemi, India’s first global CAR T-cell therapy for...
Qartemi® is India’s first global CAR T-cell therapy, locally manufactured at Immuneel’s state-of-the-art facility in Bangalore, offering lasting remission for relapsed/refractory B-cell Non-Hodgkin’s Lymphoma
First patient in India administered Bi-Specific CAR-T therapy for multiple Myeloma
A team of doctors led by acclaimed oncologist Dr Vijay Patil and including Dr Bilal Kazi, Dr Saurabh Bhave and Dr Ashay Karpe, administered the treatment here at SUNACT’s Thane centre
Hope Restored: Woman triumphs over Lymphoma with CAR-T Cell Therapy
She’s the first person in Andhra Pradesh to have been successfully treated with indigenously built therapy
President of India launches country’s first home-grown gene therapy for cancer
The accessible and affordable car-t cell therapy provides a new hope for the whole of humankind: president Droupadi Murmu
Amrita Hospital ties up with ImmunoACT to introduce CAR T-cell Therapy...
This strategic partnership between Amrita Hospital, Faridabad and IIT Bombay incubated company will ensure that patients across all segments benefit from this life-saving advanced medicine
BioVoice eMagazine July 2023 | Issue 7 | Volume 4
This edition showcases the top 10 biotechnologies to watch out for in 2023. Insightful interviews of Piyush Sohani, Managing Director, Sistema.bio India and Dr Rachna Dave, CEO & Founder of MicroGO.
Growing investment in biotech startups likely to make CAR-T therapies affordable...
Increased investments likely to boost the research and production capabilities and eventually makes the therapies affordable to those in need, says GlobalData, a leading data and analytics company.
Post NHS approval, sky is the limit for Novartis’ CAR-T therapy:...
According to GlobalData forecasts, the Novartis CAR-T therapy, Kymriah is expected to hit over $1billion sales revenue by 2023 in the US alone......……….
Pricing adjustments for CAR-T therapies likely to take place in 2018,...
A fairly comprehensive study reported in February 2018 on the Health Affairs Blog claims that Novartis could lower the price of Kymriah by two-thirds and still achieve a profit..................